产品中心 抗体 其他一抗

所有图片(1/9)

AACT Recombinant Rabbit mAb (S-897-109)

Alpha-1-antichymotrypsin,ACT,Cell growth-inhibiting gene 24/25 protein,Serpin A3,SERPINA3

价格 600.00 供应商现货 : 3-5个工作日
货号 S0B6303
规格
数量
收藏 分享

产品介绍 FAQs 评论(0)

产品规格
  • 宿主来源

    Rabbit
  • 抗原名称

    AACT
  • 分子别名

    Alpha-1-antichymotrypsin; ACT; Cell growth-inhibiting gene 24/25 protein; Serpin A3; SERPINA3
  • 免疫原

    Recombinant Protein
  • 细胞定位

    Secreted
  • Accession

    P01011
  • 克隆号

    S-897-109
  • 抗体类型

    Recombinant mAb
  • 抗体同种型

    IgG
  • 反应种属 ?

    Hu
  • 阳性样本

    human serum, human plasma
  • 纯化方式

    Protein A
  • 浓度

    0.5 mg/ml
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300

  • 储存条件

    12 months from date of receipt / reconstitution, -20 °C as supplied

  • 应用

    IHC-P ?

    WB

  • 稀释度

    应用 稀释度 推荐种属
    WB 1:1000-1:10000 Hu
    IHC-P 1:1000 Hu
背景介绍
  • Alpha-1-antichymotrypsin (AACT), also known as SERPINA3, is a serine protease inhibitor primarily synthesized in the liver and secreted into the blood. It is an acute-phase protein involved in the inflammatory response and has a molecular weight of approximately 47.651 kDa. AACT plays a crucial role in inhibiting proteases such as cathepsin G and chymase, thereby protecting cells and tissues from proteolytic damage. Elevated levels of AACT have been observed in various diseases, including Alzheimer's disease, heart failure, and multiple cancers. Its expression and glycosylation patterns can serve as potential biomarkers for disease diagnosis and prognosis.

  • 免疫印迹

    • WB result of AACT Recombinant Rabbit mAb
      Primary antibody: AACT Recombinant Rabbit mAb at 1/1000 dilution
      Lane 1: human serum lysate 5 µg
      Lane 2: human plasma lysate 5 µg
      Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
      Predicted MW: 48 kDa
      Observed MW: 60-70 kDa

  • 免疫组化

    • IHC shows positive staining in paraffin-embedded human colon. Anti-AACT antibody was used at 1/5000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

    • IHC shows positive staining in paraffin-embedded human kidney. Anti-AACT antibody was used at 1/5000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

    • IHC shows positive staining in paraffin-embedded human liver. Anti-AACT antibody was used at 1/5000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

    • IHC shows positive staining in paraffin-embedded human tonsil. Anti-AACT antibody was used at 1/5000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

    • IHC shows positive staining in paraffin-embedded human cervical squamous cell carcinoma. Anti-AACT antibody was used at 1/5000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

    • IHC shows positive staining in paraffin-embedded human hepatocellular carcinoma. Anti-AACT antibody was used at 1/5000 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

  • 组织表达图谱

    • Expression of AACT in tumor tissue.

    • Expression of AACT in human tissue.

FAQs

斯达特公司的抗体,可以回收利用几次?

我们一般不推荐客户回收利用抗体。 因为抗体使用之后缓冲体系已经发生改变,不同客户在回收抗体的保存条件上也会有差异,所以抗体回收使用效果无法保证。另外,我们对一批抗体回收验证测试,测试结果显示不同抗体可回收次数不同,一般效价越高的抗体,可重复使用的次数越多,客户可根据实验情况来确定

评论(0)